The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 19, 2023
Filed:
May. 08, 2015
Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;
F. Hoffmann-la Roche Ag, Basel, CH;
Toshihiko Ohtomo, Tokyo, JP;
Takayoshi Tanaka, Tokyo, JP;
Yasuo Sugitani, Tokyo, JP;
Oscar Puig, Jersey City, NJ (US);
Ruey-min Lee, Short Hills, NJ (US);
Gong Chen, Rutherford, NJ (US);
Anton Belousov, Penzberg, DE;
Ya-Chi Chen, Hoboken, NJ (US);
Bernhard Reis, Basel, CH;
Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;
F. Hoffmann-La Roche AG, Basel, CH;
Abstract
A method is provided for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or for determining the continuation of GPC3-targeting drug therapy for a patient treated with GPC3-targeting therapy. The method includes determining the number of an immunocyte or an expression level of a molecule expressed on the immunocyte in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the number of the immunocyte or the expression level of the molecule expressed on the immunocyte is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. GPC3-targeting drugs and drug preparations for use according to the disclosed methods are also provided.